Navigation Links
Palatin Technologies Announces Third Quarter Fiscal Year 2013 Results and Update on Development of Bremelanotide for Female Sexual Dysfunction
Date:5/14/2013

CRANBURY, N.J., May 14, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced financial results for the third quarter ended March 31, 2013. The Company also summarized end-of-Phase 2 discussions with the U.S. Food and Drug Administration (FDA) and next steps for its Phase 3 pivotal registration program for bremelanotide, its product in development as a novel treatment for female sexual dysfunction (FSD). Palatin will hold a conference call and live audio webcast later today.

End-of-Phase 2 Meeting with FDA on Bremelanotide for FSD
In the end-of-Phase 2 meeting with FDA, Palatin reached preliminary agreement on key aspects of the Phase 3 pivotal registration studies, including:

  • FSD patient population
  • Primary and key secondary efficacy endpoints
  • Study design
  • Dose selection
  • Safety monitoring
  • In addition, the FDA agreed with Palatin's position that the blood pressure and heart rate signals of bremelanotide had been adequately characterized during the Phase 2 program. The FDA also agreed with the proposed Phase 3 blood pressure monitoring program, which will consist of standardized methods for in-clinic assessment of blood pressure.

    "We view our positive meeting with the FDA as a major milestone in the development of bremelanotide for FSD. We are pleased to have concurrence from the FDA on the design and selection of efficacy endpoints of our Phase 3 clinical studies," stated Carl Spana, Ph.D., President and CEO of Palatin. "We are also pleased with the FDA's concurrence that the blood pressure monitoring program for our Phase 3 clinical studies only includes standardized methods for in-clinic assessment of blood pressure. We look forward to advancing bremelanotide for FSD towards a suc
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Palatin Technologies, Inc. To Report Fiscal Year 2013 Third Quarter Results; Teleconference and Webcast to be held on May 14, 2013
    2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-Specific Peptides for Sexual Dysfunction
    3. Palatin Technologies To Present At The 25th Annual ROTH Conference
    4. Palatin Technologies, Inc. To Present At The Cowen & Company 33rd Annual Health Care Conference
    5. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
    6. Palatin Technologies, Inc. To Report Fiscal Year 2013 Second Quarter Results; Teleconference and Webcast to be held on February 14, 2013
    7. Palatin Technologies, Inc. to Present at 15th Annual BIO CEO & Investor Conference
    8. Palatin Technologies, Inc. to Present at the 24th Annual Piper Jaffray Healthcare Conference
    9. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on November 14, 2012
    10. Palatin Technologies, Inc. To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
    11. Palatin Technologies, Inc. To Report Fiscal Year 2013 First Quarter Results; Teleconference and Webcast to be held on November 14, 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)...  Regado Biosciences, Inc. (Nasdaq: RGDO ), ... and live audio webcast on Thursday, November 6, 2014, ... 2014 financial results. Interested participants and investors ... for domestic callers or (412) 902-4276 for international callers. ... investor relations section of the Regado website at ...
    (Date:10/27/2014)... 27, 2014 The new research ... (High & Medium), Sub-type (Primary & Secondary), and ... & Transportation & Power Generation) - Trends and ... market with analysis and forecasting of the market ... Tables with 52 Figures spread through 146 Pages ...
    (Date:10/27/2014)... 2014 The “Molecular Diagnostic Market ... Technology (PCR, INAAT, DNA Sequencing), End User (Hospital, ... - Global Forecast to 2018” provides a detailed ... current market trends, and strategies impacting the global ... forecasts of the revenue and share analysis. , ...
    (Date:10/27/2014)... Mass. , Oct. 27, 2014 ... "Company"), a worldwide leader in the development and ... the life sciences research market, today announced that ... presented a novel, accurate, highly reproducible, and robust ... – routine high-throughput protein analysis on small needle ...
    Breaking Biology Technology:Regado Biosciences to Provide Third Quarter 2014 Financial Results 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 2Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 3Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 4Global Molecular Diagnostics Market Will Reach $7.9 Billion by 2018 - New Research Report by MarketsandMarkets 5Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 2Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 3Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 4Breakthrough Method to Permit Quantification of Thousands of Proteins in Needle Biopsy Samples in 12 hours Presented at Major International Scientific Meeting; Method Enabled by Pressure BioSciences' PCT Sample Preparation Platform 5
    ... EXTON, Pa., June 2, 2011 Morphotek®, Inc., a ... commenced a multi-center, phase II study of MORAb-004 for ... MORAb-004, a potentially first-in-class monoclonal antibody that specifically binds ... therapy comparing its safety and therapeutic activity at two ...
    ... a medical explanation for why exercise is good for the ... that started in Dr. Ian Phillips, lab at Keck Graduate ... 29 that keeps hearts healthy even under intense exercise. ... of why exercise is good for you," said Phillips, KGI,s ...
    ... (NASDAQ: SQNM ), a life sciences company ... its subsidiary Sequenom Center for Molecular Medicine® (Sequenom CMM) ... Valley Bank’s San Diego-based team. Sequenom will use proceeds ... of new products and other near term growth initiatives. ...
    Cached Biology Technology:Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma 2Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma 3Scientists Discover Gene Regulator That Helps Hearts Through Exercise 2Sequenom Enters Into New $30.0 Million Credit Facility 2Sequenom Enters Into New $30.0 Million Credit Facility 3Sequenom Enters Into New $30.0 Million Credit Facility 4
    (Date:10/29/2014)... number of chemicals from household and industrial products are ... bodies. But for most of them, scientists have yet ... taken the first step toward doing that by estimating ... new method is published in the ACS journal ... and colleagues note that the risks to human health ...
    (Date:10/29/2014)... in German . ... and Peter Schlögelhofer at the Max F. Perutz Laboratories ... University of Vienna dived into the process of meiosis ... display an inversion of the standard meiotic phases. The ... Nature Communications . , Meiosis is the two-step ...
    (Date:10/29/2014)... all organisms in the living world compete with ... strongly in how much they invest into their ... eager to get access to high-quality resources, while ... use of the lower-quality resources that are left ... in animal and human societies seems to fluctuate ...
    Breaking Biology News(10 mins):Meiotic cell division 'the other way round' 2Evolution of competitiveness 2Evolution of competitiveness 3
    ... used in California,s Central Valley, one of the world,s ... frog species miles from farmland. Writing in Environmental ... Pacific Tree Fogs in remote mountain areas, including national ... pesticides by the elements. California,s Central Valley is ...
    ... 25, 2013 The following statement is being issued by Robbins Geller ... Pacific Biosciences Securities Litigation SUPERIOR COURT OF THE ... IN RE PACIFIC BIOSCIENCES OF CALIFORNIA ... CIV509210 SUMMARY NOTICE OF PROPOSED SETTLEMENT OF CLASS ACTION Hon. Marie ...
    ... researchers have developed a computer-aided method that uses ... rapid advances toward personalized health care, disease management ... V. Chawla and his doctoral student, Darcy A. ... Recommendation Engine (CARE) for personalized disease risk predictions ...
    Cached Biology News:Pesticides contaminate frogs from Californian National Parks 2Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 2Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 3Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 4Notre Dame researchers develop system that uses a big data approach to personalized healthcare 2
    This antibody detects an ~25 kDa band, corresponding to the expected molecular mass of Rab3A, on immunoblots. The antibody specificity is confirmed in peptide inhibition immunoblotting studies....
    ... reactive against the complex IV assembly factor SURF1. ... cultured cells. SURF1 is an important assembly factor ... participate in the folding of subunit II and ... SURF1, particularly ones that result in an absence ...
    100 g monoclonal antibody which can immunocapture ~10 g of Complex IV from heart mitochondria. Also included are 2 mg of bovine heart mitochondria for control immunocapture....
    Rabbit polyclonal to GPR56 ( Abpromise for all tested applications). entrezGeneID: 9289 SwissProtID: Q9Y653...
    Biology Products: